United States, Nov. 14 -- In today's rapidly evolving health care landscape, pharmaceutical and biotechnology companies face mounting pressure to accelerate drug development while maintaining rigorous compliance with global regulatory standards. And the influx of real-world, biomarker and digital protocol data; hybrid and decentralized trial designs; and increasing demand for patient centricity have introduced new complexities that legacy systems struggle to manage efficiently.To address these challenges head-on, SAS - a global leader in clinical research analytics - today announced the general availability of SAS Clinical Acceleration. The cornerstone solution built on the SAS(R) Viya(R) platform modernizes and streamlines clinical trial d...